GHRP-6 vs Ipamorelin
Both GHRP-6 and Ipamorelin are used for growth-hormone. Here's how their evidence, dosing, and regulatory status actually compare.
GHRP-6
Evidence BGrowth Hormone Releasing Peptide 6
An older GHS that produces strong appetite stimulation in addition to GH release. Largely supplanted by Ipamorelin and GHRP-2 for clinical use but still common in research stacks.
View full GHRP-6 profile →Ipamorelin
Evidence BIpamorelin Acetate
A selective growth hormone secretagogue that triggers GH release from the pituitary without significantly raising cortisol or prolactin. The safest GH peptide with the fewest side effects.
View full Ipamorelin profile →Side-by-Side
| Attribute | GHRP-6 | Ipamorelin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — research compound | Not FDA-approved — Category 1 (compounding allowed) |
| Typical Dose | 100–300 mcg, 1–3 times daily (subcutaneous) | 100–300 mcg before bed (subcutaneous) |
| Clinics Indexed | 64 | 195 |
| Categories | growth-hormone, appetite | growth-hormone, anti-aging |
Key reported benefits — GHRP-6
- ✓GH release
- ✓Appetite stimulation
- ✓Cytoprotection
Key reported benefits — Ipamorelin
- ✓Clean GH release
- ✓Improved sleep quality
- ✓Fat reduction
- ✓Joint health
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.